Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Researchers in the USA have identified a gene that plays a key role in slowing the movement of lung cancer to other parts of the body.
The study, published in the journal Molecular Cell, aimed to shed light on why lung cancer can spread throughout the body, a process that often happens very quickly.
The researchers investigated a known anti-cancer gene called LKB1. Around one fifth of people with lung cancer are missing this gene, and as a result experience particularly aggressive forms of the disease.
In their study, the researchers discovered that LKB1 communicates with another gene, DIXDC1.
When “switched on”, DIXDC1 causes tumour cells to stick to each other. However, when it is inactive the cells can break away and travel to other parts of the body where they embed themselves and can cause other tumours.
The researchers believe that this finding could pave the way for new lung cancer treatments.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79